LONDON–(BUSINESS WIRE)–Oct 7, 2021–
Kanabo, one of Europe’s fastest-growing medical cannabis R&D companies that focuses on the distribution of cannabis-derived products for medical patients, and non-THC products for CBD consumers, has signed a partnership agreement with the Medocann Pharma Ltd. to develop new products that will target specific medical conditions. The deal gives Kanabo exclusive distribution rights to the co-developed products into the growing German and UK cannabis markets.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211006005920/en/
Kanabo Announces Partnership With Medocann Group to Exclusively Develop and Distribute Unique Cannabis Strains & Products for UK and German Markets (Photo: Business Wire)
Medocann is an…